CL2008001887A1 - Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. - Google Patents

Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.

Info

Publication number: CL2008001887A1
Authority: CL; Chile
Prior art keywords: proteases; par; understands; union; antigen
Prior art date: 2007-06-29

Application number

CL200801887A

Other languages

English (en)

Inventor

Shaw-Fen Sylvia Virca G Duk Hu

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-29

Filing date

2008-06-25

Publication date

2008-10-03

2008-06-25 Application filed by Amgen Inc filed Critical Amgen Inc

2008-10-03 Publication of CL2008001887A1 publication Critical patent/CL2008001887A1/es

Links

NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 title 1
102000035195 Peptidases Human genes 0.000 title 1
108091005804 Peptidases Proteins 0.000 title 1
239000004365 Protease Substances 0.000 title 1
102100037132 Proteinase-activated receptor 2 Human genes 0.000 title 1
101710121435 Proteinase-activated receptor 2 Proteins 0.000 title 1
239000000427 antigen Substances 0.000 title 1
102000036639 antigens Human genes 0.000 title 1
108091007433 antigens Proteins 0.000 title 1
102000039446 nucleic acids Human genes 0.000 title 1
108020004707 nucleic acids Proteins 0.000 title 1
150000007523 nucleic acids Chemical class 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
102000005962 receptors Human genes 0.000 title 1
108020003175 receptors Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Obesity (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CL200801887A 2007-06-29 2008-06-25 Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. CL2008001887A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94726407P	2007-06-29	2007-06-29
US5809408P	2008-06-02	2008-06-02

Publications (1)

Publication Number	Publication Date
CL2008001887A1 true CL2008001887A1 (es)	2008-10-03

Family

ID=39718522

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200801887A CL2008001887A1 (es)	2007-06-29	2008-06-25	Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.

Country Status (17)

Country	Link
US (3)	US8357367B2 (es)
EP (2)	EP2562186A1 (es)
JP (1)	JP5255633B2 (es)
KR (1)	KR20100033523A (es)
CN (1)	CN101743254A (es)
AR (1)	AR067199A1 (es)
AU (1)	AU2008271073B2 (es)
BR (1)	BRPI0813242A2 (es)
CA (1)	CA2690538A1 (es)
CL (1)	CL2008001887A1 (es)
EA (1)	EA200901436A1 (es)
ES (1)	ES2406429T3 (es)
IL (1)	IL202259A0 (es)
MX (1)	MX2009013824A (es)
PE (1)	PE20090769A1 (es)
TW (1)	TW200909447A (es)
WO (1)	WO2009005726A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2313110A1 (en) *	2008-08-05	2011-04-27	Boehringer Ingelheim International GmbH	Effectors of par-2 activation and their use in the modulation of inflammation
JO3246B1 (ar) *	2009-09-09	2018-03-08	Regeneron Pharma	اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
US9708375B2 (en)	2013-03-15	2017-07-18	Amgen Inc.	Inhibitory polypeptides specific to WNT inhibitors
EP3041863A4 (en)	2013-09-05	2017-08-16	Amgen Inc.	Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
KR20160060120A (ko)	2013-09-25	2016-05-27	버텍스 파마슈티칼스 인코포레이티드	Ｐａｒ-2 신호전달 경로의 억제제로서 유용한 이미다조피리다진
CA2949237C (en)	2014-05-16	2022-08-23	Amgen Inc.	Assay for detecting th1 and th2 cell populations
CA3056011A1 (en)	2017-03-14	2018-09-20	Amgen Inc.	Control of total afucosylated glycoforms of antibodies produced in cell culture
MA49886A (fr) *	2017-03-16	2020-06-24	Medimmune Ltd	Anticorps anti-par2 et leurs utilisations
WO2019123316A1 (en) *	2017-12-22	2019-06-27	Glycom A/S	Composition comprising hmos for preventing or reducing nociception
CN111954719B (zh)	2018-03-26	2025-07-18	美国安进公司	细胞培养物中产生的抗体的总去岩藻糖基化糖型
EP3946332A1 (en)	2019-04-05	2022-02-09	Université de Bretagne Occidentale	Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
BR112022005583A2 (pt)	2019-09-26	2022-09-20	Amgen Inc	Métodos para a produção de composições de anticorpos
EP4162257A1 (en)	2020-06-04	2023-04-12	Amgen Inc.	Assessment of cleaning procedures of a biotherapeutic manufacturing process
PE20231187A1 (es)	2020-08-18	2023-08-15	Cephalon Llc	Anticuerpos anti-par-2 y metodos de uso de los mismos
KR20230087539A (ko)	2020-10-15	2023-06-16	암젠 인크	항체 생산 방법에서의 상대적인 비결합 글리칸
TW202317614A (zh)	2021-06-07	2023-05-01	美商安進公司	使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
WO2023059607A1 (en)	2021-10-05	2023-04-13	Amgen Inc.	Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
WO2024220916A1 (en)	2023-04-20	2024-10-24	Amgen Inc.	Methods of determining relative unpaired glycan content
WO2025038600A1 (en)	2023-08-14	2025-02-20	Amgen Inc.	Methods for reducing yellow color
WO2025101820A1 (en)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5011912A (en)	1986-12-19	1991-04-30	Immunex Corporation	Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US6010902A (en)	1988-04-04	2000-01-04	Bristol-Meyers Squibb Company	Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
ATE160379T1 (de)	1990-10-29	1997-12-15	Chiron Corp	Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
US5582996A (en)	1990-12-04	1996-12-10	The Wistar Institute Of Anatomy & Biology	Bifunctional antibodies and method of preparing same
DE4118120A1 (de)	1991-06-03	1992-12-10	Behringwerke Ag	Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
CA2103059C (en)	1991-06-14	2005-03-22	Paul J. Carter	Method for making humanized antibodies
US5262522A (en)	1991-11-22	1993-11-16	Immunex Corporation	Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5869619A (en)	1991-12-13	1999-02-09	Xoma Corporation	Modified antibody variable domains
EP0672141B1 (en)	1992-10-23	2003-05-14	Immunex Corporation	Methods of preparing soluble, oligomeric proteins
US5457035A (en)	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
US5763575A (en) *	1993-07-26	1998-06-09	Cor Therapeutics, Inc.	Agonist and antagonist peptides of the C140 receptor
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
ES2301183T3 (es)	1996-12-03	2008-06-16	Amgen Fremont Inc.	Anticuerpo completamente humano que se une al receptor del egfr.
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
AU770555B2 (en)	1998-08-17	2004-02-26	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
US6833268B1 (en)	1999-06-10	2004-12-21	Abgenix, Inc.	Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB9928787D0 (en)	1999-12-03	2000-02-02	Medical Res Council	Direct screening method
WO2001052883A1 (en)	2000-01-20	2001-07-26	Amgen Inc.	Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics
GB0025144D0 (en)	2000-10-13	2000-11-29	Medical Res Council	Concatenated nucleic acid sequences
US20030191056A1 (en)	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2004080373A2 (en)	2003-03-11	2004-09-23	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
US20040202995A1 (en)	2003-04-09	2004-10-14	Domantis	Nucleic acids, proteins, and screening methods
JP2008535823A (ja)	2005-03-25	2008-09-04	キュラジェンコーポレイション	テネイシンの主要な抗原に対する抗体
US7888482B2 (en) *	2006-02-10	2011-02-15	Amgen Inc.	Antibodies that bind PAR-2

2008
- 2008-06-25 CL CL200801887A patent/CL2008001887A1/es unknown
- 2008-06-26 BR BRPI0813242-9A patent/BRPI0813242A2/pt not_active IP Right Cessation
- 2008-06-26 AU AU2008271073A patent/AU2008271073B2/en not_active Ceased
- 2008-06-26 MX MX2009013824A patent/MX2009013824A/es active IP Right Grant
- 2008-06-26 CA CA2690538A patent/CA2690538A1/en not_active Abandoned
- 2008-06-26 JP JP2010514830A patent/JP5255633B2/ja not_active Expired - Fee Related
- 2008-06-26 KR KR1020107002008A patent/KR20100033523A/ko not_active Ceased
- 2008-06-26 EA EA200901436A patent/EA200901436A1/ru unknown
- 2008-06-26 CN CN200880022222A patent/CN101743254A/zh active Pending
- 2008-06-26 ES ES08768823T patent/ES2406429T3/es active Active
- 2008-06-26 EP EP12178869A patent/EP2562186A1/en not_active Withdrawn
- 2008-06-26 US US12/215,304 patent/US8357367B2/en active Active
- 2008-06-26 EP EP08768823A patent/EP2167543B1/en active Active
- 2008-06-26 WO PCT/US2008/008037 patent/WO2009005726A1/en not_active Ceased
- 2008-06-27 PE PE2008001101A patent/PE20090769A1/es not_active Application Discontinuation
- 2008-06-27 TW TW097124011A patent/TW200909447A/zh unknown
- 2008-06-27 AR ARP080102779A patent/AR067199A1/es unknown
2009
- 2009-11-22 IL IL202259A patent/IL202259A0/en unknown
2012
- 2012-06-25 US US13/532,242 patent/US8470556B2/en active Active
2013
- 2013-06-05 US US13/910,413 patent/US20140170166A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20130011878A1 (en)	2013-01-10
JP5255633B2 (ja)	2013-08-07
ES2406429T3 (es)	2013-06-07
EP2562186A1 (en)	2013-02-27
TW200909447A (en)	2009-03-01
US20140170166A1 (en)	2014-06-19
MX2009013824A (es)	2010-04-12
AR067199A1 (es)	2009-09-30
US8357367B2 (en)	2013-01-22
AU2008271073A1 (en)	2009-01-08
US8470556B2 (en)	2013-06-25
WO2009005726A1 (en)	2009-01-08
CN101743254A (zh)	2010-06-16
BRPI0813242A2 (pt)	2015-08-18
EP2167543A1 (en)	2010-03-31
JP2010532165A (ja)	2010-10-07
EA200901436A1 (ru)	2010-10-29
IL202259A0 (en)	2010-06-16
AU2008271073B2 (en)	2012-05-03
KR20100033523A (ko)	2010-03-30
PE20090769A1 (es)	2009-07-23
US20110059063A1 (en)	2011-03-10
CA2690538A1 (en)	2009-01-08
EP2167543B1 (en)	2013-04-03

Similar Documents

Publication	Publication Date	Title
CL2008001887A1 (es)	2008-10-03	Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
CL2009000459A1 (es)	2010-12-10	Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
DK2824183T3 (da)	2020-09-28	Fremgangsmåde til fremstilling af bispecifikke antistoffer
CL2008001128A1 (es)	2008-06-13	Asparraginasa; secuencia de acido nucleico que la codifica; construccion de acidos nucleicos, vector y celula huesped; metodo para producir asparraginasa; composicion que comprende variante; uso de la variante de asparraginasa; proceso de elaboracion
CL2007002989A1 (es)	2008-05-16	Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3.
BRPI0610197B8 (pt)	2021-05-25	anticorpo de ligação à esclerostina, processo para a produção do mesmo, composição farmacêutica que compreende o dito anticorpo e vetor de clonagem ou expressão
CL2007002987A1 (es)	2008-06-06	Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para tratar enfermedades relacionadas con notch3.
CL2013001403A1 (es)	2014-08-08	Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
CL2014001293A1 (es)	2014-12-05	Anticuerpo monocional o fragmento enlazante a antigeno del mismo, especifico para proteinas de citomegalovirus humano (hcmv); molecula de acido nucleico que lo codifica; celula huesped; metodo de produccion; composicion que lo comprende; y su uso para el tratamiento de infeccion por hcmv (div sol 84-2011)
CL2007003161A1 (es)	2008-05-30	Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como
BR112014012275A2 (pt)	2017-05-30	purificação de proteína com a utilização de tampão bis-tris
CL2013002040A1 (es)	2014-01-24	Anticuerpo biespecifico o fragmento del mismo que se une especificamente a il-13 e il-14; molecula de acido nucleico que lo codifica; vector; celula; composicion farmaceutica; y sus usos (div.sol.n°3037-08).
CL2007003623A1 (es)	2008-08-08	Proteina de enlace multivalente monocatenaria con funcion efectora; acido nucleico que la codifica; vector y celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y metodo para tratar trastornos proliferativos.
BR112015027812A2 (pt)	2017-07-25	processo contínuo de multietapa para purificação de anticorpos
PE20120543A1 (es)	2012-05-23	Anticuerpo anti-tau ps422
CL2008003784A1 (es)	2009-08-14	Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo
CL2008000839A1 (es)	2008-09-26	Anticuerpo anti-ige/m1'; acido nucleico que lo codifica; vector y celula huesped; proceso de produccion; composicion que comprende al anticuerpo; y su uso para tratar trastornos mediados por ige.
CL2013001831A1 (es)	2013-11-08	Proteina de enlace multivalente y multiespecifica que une a il-1 alfa y beta; conjugado que la comprende; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y sus usos.
CL2007003291A1 (es)	2008-07-04	Anticuerpo monoclonal humano aislado que enlaza la proteina btla o fragmentos del mismo; acido nucleico que lo codifica; metodo de produccion; composicion e inmunoconjugado que los comprende; y metodo para inhibir el crecimiento de celulas de tumor e
CL2013000074A1 (es)	2013-12-06	Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos.
ZA200804346B (en)	2009-04-29	Anit-Aß globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
AR063429A1 (es)	2009-01-28	Anticuerpos anti- htnfalfa cristalinos
WO2009105670A3 (en)	2009-11-26	Substrates for multiplexed assays and uses thereof
DK1877192T3 (da)	2013-02-04	Fremgangsmåde til fremstilling af fibermateriale
EP3505538A4 (en)	2020-03-18	METHOD FOR PRODUCING AN ANTIBODY FUSION PROTEIN